BCLI (Brainstorm Cell Therapeutics) 1-Year ROIIC % : -1,690.55% (As of Mar. 2026)


BCLI Brainstorm Cell Therapeutics Inc BCLI
28 GF Score
Price $1.01
! 2 Warning Signs
View Full Analysis

What is Brainstorm Cell Therapeutics 1-Year ROIIC %?

Brainstorm Cell Therapeutics BCLI -6.48% 28 1-Year ROIIC % is -1,690.55 as of Mar. 2026. GuruFocus rates BCLI with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,341 Biotechnology companies, Brainstorm Cell Therapeutics ranks worse than 94.56% on this metric.

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Brainstorm Cell Therapeutics's 1-Year ROIIC % for the quarter that ended in Mar. 2026 was -1,690.55%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Brainstorm Cell Therapeutics's 1-Year ROIIC % or its related term are showing as below:

BCLI's 1-Year ROIIC % is ranked worse than
94.56% of 1341 companies
in the Biotechnology industry
Industry Median: -8.77 vs BCLI: -1690.55

Brainstorm Cell Therapeutics  (OTCPK:BCLI) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Brainstorm Cell Therapeutics 1-Year ROIIC % Related Terms


Brainstorm Cell Therapeutics 1-Year ROIIC % Historical Data

* Premium members only.

The historical data trend for Brainstorm Cell Therapeutics's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brainstorm Cell Therapeutics 1-Year ROIIC % Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
1-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -222.31 -74.67 -86.26 -1,993.05 -1,298.51

Brainstorm Cell Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 532.95 -1,542.46 -1,606.67 -1,298.51 -1,690.55

BCLI vs ADAPY, APRE, JSPR: 1-Year ROIIC % Comparison

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brainstorm Cell Therapeutics 1-Year ROIIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's 1-Year ROIIC % falls into.


BCLI
28GF Score
Brainstorm Cell Therapeutics Inc BCLI
1-Year ROIIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brainstorm Cell Therapeutics 1-Year ROIIC % Calculation

Brainstorm Cell Therapeutics's 1-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -8.91 (Mar. 2026) - -12.308 (Mar. 2025) )/( 4.604 (Mar. 2026) - 4.805 (Mar. 2025) )
=3.398/-0.201
=-1,690.55%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Frequently Asked Questions Learn more about 1-Year ROIIC % →
What does a 1-Year ROIIC % of -1,690.55 mean?
Brainstorm Cell Therapeutics (BCLI) has a 1-Year ROIIC % of -1,690.55 as of Mar. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Brainstorm Cell Therapeutics and its competitors. According to the industry distribution chart, Brainstorm Cell Therapeutics ranks #1268 out of 1341 companies in the Biotechnology industry, placing it in the top 94.6%.
Is Brainstorm Cell Therapeutics' 1-Year ROIIC % too high?
Brainstorm Cell Therapeutics' current 1-Year ROIIC % is -1,690.55. Based on the distribution chart, Brainstorm Cell Therapeutics ranks #1268 out of 1341 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Brainstorm Cell Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Brainstorm Cell Therapeutics' 1-Year ROIIC % compare to ADAPY and APRE?
According to the Biotechnology industry distribution chart, Brainstorm Cell Therapeutics ranks #1268 out of 1341 companies for 1-Year ROIIC %. This places Brainstorm Cell Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Biotechnology company?
A good 1-Year ROIIC % depends on the Biotechnology industry context. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Brainstorm Cell Therapeutics and its competitors. Brainstorm Cell Therapeutics's current 1-Year ROIIC % is -1,690.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brainstorm Cell Therapeutics stock overvalued right now?
Brainstorm Cell Therapeutics (BCLI) has a current 1-Year ROIIC % of -1,690.55. The current 1-Year ROIIC % is -1,690.55. Brainstorm Cell Therapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Brainstorm Cell Therapeutics (BCLI), the current 1-Year ROIIC % is -1,690.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brainstorm Cell Therapeutics Business Description

Address 1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
28GF Score

Get the complete analysis for BCLI

1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.01
Price